Injectafer® approved in the U.S. for the treatment of
iron deficiency
in patients with
heart failure

2023-06-05
PRNewswire
上市批准AHA会议
Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with
symptomatic heart failure
who have
iron deficiency
ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo Group company, approval for Injectafer
® for the treatment of
iron deficiency
in adult patients with
heart failure
and New York Heart Association class II/III* to improve exercise capacity.1
"We are very pleased that the FDA has approved the
heart failure
label extension of Injectafer
®, and congratulate our partner on this milestone", said Hervé Gisserot, General Manager of CSL Vifor. "Every second patient with
chronic heart failure
suffers from
iron deficiency
, with a significant number of patients either not being diagnosed or inadequately treated for
iron deficiency
. We are confident that Injectafer® can make a meaningful contribution to achieve key therapeutic goals in the treatment of these patients."
The value of treating
iron deficiency
in
heart failure
patients has been clearly recognized by leading guideline committees such as the American Heart Association, the American College of Cardiology, the
Heart Failure
Society of America as well as the European Society of Cardiology.
The FDA approval was supported by CSL Vifor's randomized placebo-controlled study, CONFIRM-
HF
(NCT01453608), that evaluated the efficacy and safety of ferric carboxymaltose in adult patients with
symptomatic heart failure
and
iron deficiency
. The treatment over a 1-year period resulted in a significant and sustainable improvement in exercise capacity in this patient population.2
CSL Vifor has granted American Regent, Inc., a Daiichi Sankyo Group company, an exclusive right to develop, manufacture and market Injectafer® in the United States. Please also visit https://americanregent.com/news/ to access the public announcement from American Regent, which does not form a part of this release.
*The New York Heart Association Functional Classification is used by Healthcare Professionals to classify patients'
heart failure
based on the severity of their symptoms. Patients who have a slight or marked limitation of their physical activity due to
fatigue
, palpitation and/or
dyspnea
are considered to have class II or class III
heart failure
, respectively.3
About
CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in
iron deficiency
and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Injectafer / Ferinject
Injectafer® / Ferinject® (ferric carboxymaltose) is an i.v. iron therapy with market authorization in 85 countries by May 2023. It has a track record of delivering significant value to patients and healthcare systems which is based on extensive clinical data and more than 25 million patient years of exposure. Injectafer is the most extensively studied IV iron.4,5
Injectafer is indicated for the treatment of
iron deficiency
in patients with
heart failure
;
iron deficiency anemia (IDA)
in adult and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron; and adult patients with IDA who have non-dialysis dependent chronic kidney disease.1
References:
1 Injectafer [package insert]. Shirley, NY: American Regent, Inc.; May 2023.
2 Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with
symptomatic heart failure
and
iron deficiency
(CONFIRM-HF). Eur Heart J. 2015 Mar 14;36(11):657-68.
3 Classes of
Heart Failure
. American Heart Association. May 2017. https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure
4 Data on file. Injectafer Studies. Daiichi Sankyo Inc., Basking Ridge, NJ.
5 CSL Vifor Press Release. https://www.viforpharma.com/ferinjectr-approved-china-treatment-iron-deficiency-adult-patients. Accessed May 2023.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
铁缺乏,心脏衰竭,慢性心力衰竭
[+4]
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。